AMERSA

AMERSA

Call Us: (401) 615-4047 | Contact Us AMERSA on Twitter AMERSA on LinkedIn AMERSA on BlueSky

Make a Donation Pay a Past-Due Balance Join Our Mailing List
  • About
    • What is AMERSA
    • Board of Directors
    • Donate to AMERSA
    • Contact Us
  • Membership
    • Get to Know AMERSA
    • Join / Renew
    • Who We Are
    • Member Center
    • Special Interest Groups
    • Career Opportunities
    • Professional & Academic Advancement Opps
  • Conference
    • Annual Conference
    • Conference Sponsorship
    • Conference Exhibitor Information
    • Policy and Procedures for AMERSA Events
    • 2024 Conference Materials
    • Past Conference Resources
  • Journal
    • Journal Home
    • About Us
    • Member Access to Journal
    • Author Instructions and Submission
    • SAj Blog
    • SAj Annual Awards
    • SAj Editorial Scholar Program
  • Advocacy
    • AMERSA Advocacy
    • Position Statements
    • Submit a Position Statement
    • Letters of Support
    • Public Comments
  • Sustainability
    • Initiatives
    • Resources
  • Education
    • AMERSA Podcast Series
    • AMERSA Webinars
    • Core Competencies – AMERSA in the 21st Century
    • Resources
  • Awards
    • AMERSA Awards
    • Current Award Winners
    • Past Award Winners

The Authors’ Own Words: Counselor training and attitudes toward pharmacotherapies for opioid use disorder

Mar 23, 2016 by AMERSA

We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work.

Counselor training and attitudes toward pharmacotherapies for opioid use disorder
Lydia Aletraris , Mary Bond Edmond , Maria Paino , Dail Fields , Paul M. Roman
Substance Abuse
Vol. 37, Iss. 1, 2016

Our study demonstrated that counselors held varying degrees of knowledge and opinions regarding the acceptability of buprenorphine and methadone, with 20% of counselors having insufficient knowledge about either medication. Even though counselors do not prescribe medications, their lack of knowledge regarding effectiveness is a significant barrier to the acceptance of these treatments in routine clinical practice. Acceptance was higher for buprenorphine and other medications used for opioid use disorder, than it was for methadone. The stigma facing opioid agonist medications, particularly methadone, suggests that they may be seen as less acceptable than other treatment approaches. Nevertheless, we found no significant differences between counselors’ ratings of buprenorphine and naltrexone. Our findings suggest that medication-specific training is an effective strategy for encouraging the acceptance and diffusion of opioid agonist medications.

————————————————————————————————-
Our newly released issue is now online —> January-March 2016.
————————————————————————————————-

Filed Under: SAj Blog, The Authors' Own Words

The Authors’ Own Words: Do alcohol advertisements for brands popular among underage drinkers have greater appeal among youth and young adults?

Mar 22, 2016 by AMERSA

We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work.

Do alcohol advertisements for brands popular among underage drinkers have greater appeal among youth and young adults?
Michael Siegel , William DeJong , Daryl Cioffi , Lucero Leon-Chi , Timothy S. Naimi , Alisa A. Padon , David H. Jernigan , Ziming Xuan
Substance Abuse
Vol. 37, Iss. 1, 2016

This study is the first to compare the extent of youth appeal of alcohol advertisements for brands popular among underage drinkers vs. brands unpopular among underage drinkers. We found that the advertisements for more popular brands were significantly more likely to be perceived as appealing to youth. This research is important for two reasons. First, it informs the debate about whether alcohol companies are targeting youth with their advertising. If youth-oriented brands are more likely to contain youth-oriented content, this could be an indication that the companies are preferentially trying to reach underage youth. Second, the research may help shed light on the debate about whether alcohol advertising is effective in influencing youth drinking behavior. If brands whose alcohol ads appeal more heavily to youth turn out to be the same brands that are popular among youth, this could be an indication that the advertising is influencing youth brand choices.

—

Our newly released issue (January-March 2016) is now online!

Filed Under: SAj Blog, The Authors' Own Words

SAj Volume 37, Issue 1 Is Now Online!

Mar 21, 2016 by AMERSA

We’re pleased to tell you that SAj’s Volume 37, Issue 1 is now available online! This is a double issue with a special section entitled “From Education to Implementation: Addressing the Opioid Misuse Epidemic.” In particular, our editorial serves as an introduction to the issue and describes the overarching themes you can expect in this issue.

In particular, we’d like to thank American Academy of Addiction Psychiatry (AAAP) and their Providers’ Clinical Support System for Opioid Therapies (PCSS-O) for partnering with us again to bring this issue to light.

As always, we welcome your comments via email and Twitter.

Filed Under: SAj Blog, Updates

The Authors’ Own Words: A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice

Mar 18, 2016 by AMERSA

We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work.

A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice
Shane R. Mueller , Alexander Y. Walley , Susan L. Calcaterra , Jason M. Glanz , Ingrid A. Binswanger
Substance Abuse
Vol. 36, Iss. 2, 2015

Drug overdose mortality from opioids has emerged as an epidemic in the United States. Medical providers are responsible for prescribing opioids and educating patients in many health care settings. Naloxone is an opioid antagonist which is FDA approved to reverse respiratory depression caused by opioid overdose. There is emerging evidence that community overdose education and take-home naloxone rescue kits is a promising intervention for reducing fatalities from overdose. Our review explores the role of medical providers in prescribing naloxone for take-home use and suggests that this is a promising intervention which may be used to address the opioid overdose epidemic.

Filed Under: SAj Blog, The Authors' Own Words

The Authors’ Own Words: Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence

Mar 17, 2016 by AMERSA

We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work.

Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence
Heide Jackson , Kara Mandell , Kimberly Johnson , Debanjana Chatterjee , David J. Vanness
Substance Abuse
Vol. 36, Iss. 2, 2015

This study assesses the cost-effectiveness of XR-NTX for the treatment of opioid dependence. We find that public payors may be interested in adopting XR-NTX if they are willing to pay an additional $72 dollars per patient per day beyond treating patients with methadone maintenance treatment. The cost-effectiveness analysis is one component that may guide policy decisions; other factors like patient preferences and the effectiveness of treatment for other comorbid conditions may help determine the best course of treatment for particular subgroups.

Filed Under: SAj Blog, The Authors' Own Words

  • « Previous Page
  • 1
  • …
  • 79
  • 80
  • 81
  • 82
  • 83
  • …
  • 88
  • Next Page »

Copyright © 2025
Site by: web360